INS and hyperlipidemia: T2DM is chiefly characterized by the decrease in insulin secretion or decreased sensitivity of target organs to insulin, which in turn leads to hyperglycemia, hyperlipidemia, and the increase in glucose production in the liver (Dao et al., 2023).